Devonian Health Group (CVE:GSD) Stock Price Up 12.2% – Time to Buy?

Shares of Devonian Health Group Inc. (CVE:GSD) were up 12.2% on Thursday . The stock traded as high as C$13.75 and last traded at C$13.75. Approximately 1,000 shares were traded during trading, a decline of 35% from the average daily volume of 1,536 shares. The stock had previously closed at C$12.25.

Devonian Health Group Stock Performance

The company has a current ratio of 1.07, a quick ratio of 7.82 and a debt-to-equity ratio of 16.36. The stock’s 50-day moving average price is C$12.00 and its 200-day moving average price is C$11.33. The company has a market capitalization of C$38.03 million, a P/E ratio of -4.98 and a beta of 1.14.

Devonian Health Group Company Profile

Devonian Health Group Inc engages in the development of botanical drugs. Its lead product candidate is Thykamine, completed Phase IIa clinical trial product for the treatment of ulcerative colitis and atopic dermatitis. The company also develops Pantoprazole Magnesium for the treatment of gastric; Cleo-35 for the treatment of hormonal acne in women; and value-added products for dermo-cosmetics. In addition, the company acquires drug and health product licenses; and distributes pharmaceutical products.